Leadership

Sarah Ghosh, U.S. scientific marketing lead in oncology at Regeneron, discusses developing and adapting the narrative for a medication for every global market.

Rena Denoncourt, chief operating officer at Corsera Health, discusses the operational challenges of building a startup and how she balances prioritization with the flexibility drug development demands.

Dr. Nick Botwood, chief medical officer and head of research and development at Syndax Pharmaceuticals, draws on his career to explain what separates good R&D organizations from great ones.

A career Q&A with Professor Patrick T. Harker, B.S., M.S., Ph.D., of the Wharton School of the University of Pennsylvania.

Ken Banta and Craig Tooman on why the best leaders win by asking better questions — not just chasing more data — and what that means for drug development, funding and AI in the years ahead.

Abu Dhabi is expanding its role in global biopharmaceutical manufacturing through strategic investments, advanced infrastructure, and international partnerships designed to accelerate biologics production, innovation, and supply chain resilience.

Sanofi Chief Digital Officer Emmanuel Frenehard on scaling AI across a Big Pharma global enterprise and why a strategy of concentrated AI bets — not scattered pilots — can better drive real transformation without losing sight of governance, culture or patients.

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 billion patent cliff, the pricing pressures of the Inflation Reduction Act, and shifting regulatory dynamics.

Jeff Talbot of Roseman University of Health Sciences discusses how Las Vegas is positioning itself as a growing life sciences hub by offering cost-effective laboratory space, access to capital, and a flexible environment for biotech startups and emerging companies.

As the executive insights in our June issue illustrate, breakthroughs in pharma are rarely the result of a single discovery but are the product of organizations — and people — designed to keep moving forward.

Fresh off the HBA's Honorable Mentor award, Rick Winningham, CEO of Theravance Biopharma, reflects on a career defined by cultivating the cultures driving the science.

The driving force behind Lilly’s Medicine Foundry on transforming the discovery-to-production handoff.

David Coman, CEO, BGBx, explains how the firm's rebranding reflects a broader shift in biopharma commercialization, where integrating consulting, communications, and a three-dimensional science framework is increasingly necessary for companies.

Drawing on nearly two decades in biotech finance,Troy Ignelzi outlines why operational discipline, strategic storytelling, and long-term conviction have become essential survival tools in an increasingly unforgiving life sciences market.

Toragen CEO Sandra Coufal, MD, discusses why the company is targeting HPV’s overlooked E5 protein, positioning its small-molecule therapy as a potential complement to checkpoint inhibitors like Keytruda across HPV-driven cancers.

Sandra Coufal, MD, CEO of Toragen, says the company is positioning its HPV E5 inhibitor TGN-S15 not as a competitor to Merck’s Keytruda, but as a combination partner designed to enhance checkpoint inhibition.

Sandra Coufal, MD, CEO of Toragen, explains how the company’s Scientific Advisory Board was built to provide highly specialized expertise around HPV biology, immuno-oncology, and clinical development as TGN-S15 advances through trials.

FDA undergoes leadership upheaval, leaving key drug and biologics divisions under interim control and raising concerns over regulatory continuity amid turnover at the agency’s highest levels.

Toragen’s partnership with the Bill & Melinda Gates Foundation highlights how global health priorities and commercial biotech strategy can align around one of the world’s deadliest HPV-driven cancers.

BeOne Medicines’ John Oyler on building an oncology pharma power from a disruptive idea — and playing the long game on speed, science and scale.

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares.

It’s also about knowing when you’re stuck and need a reset.

Jamie Singer and Matt Flora discuss how cybersecurity threats in pharma are evolving beyond ransomware to include data extortion, supply chain attacks, and AI-driven risks.

In an exclusive Q&A, Dean Erhardt discusses how fragmented onboarding processes delay therapy starts, along with noting how poor communication, limited visibility, and system misalignment is driving patient disengagement.

President Trump is reportedly planning to dismiss FDA Commissioner Marty Makary, adding further leadership uncertainty across U.S. health agencies.